Clinical trials
PD-1 clinical trials
Below are recruiting pd-1 clinical trials, each written for real people, not researchers. We’re tracking 300 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06865339RecruitingPhase 2
Radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
The Bronx, New YorkAges 18 years+ - NCT06841679RecruitingPhase 2/Phase 3
Testing utidelone plus chemo for untreated stomach cancer
This trial tests a new capsule (utidelone) combined with standard chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It aims to see if this combination works better than current options.
Hialeah, FloridaAges 18 years+ - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06812858RecruitingPhase 2
PD-1 inhibitor maintenance after stem cell transplant for Hodgkin lymphoma
This trial tests whether a PD-1 inhibitor (a type of immunotherapy) given after an autologous stem cell transplant can help prevent Hodgkin lymphoma from coming back in people at high risk of relapse.
AstanaAges 18–70 - NCT06794073Recruiting
Combination therapy for advanced liver cancer
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06788171RecruitingPhase 2
Combined therapy for colorectal cancer with liver spread
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
Fuzhou, FujianAges 18–75 - NCT05978102RecruitingPhase 1/Phase 2
Study of STI-7349 for advanced solid cancers
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
Yiwu, ZhejiangAges 18–80 - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
Phoenix, ArizonaAges 18 years+ - NCT06767007RecruitingPhase 2
Radiation plus immunotherapy for recurrent rectal cancer
This trial studies a combination of SBRT (a precise kind of radiation) and an immunotherapy drug (PD-1 antibody) for people whose rectal cancer has come back in the pelvis and cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or stop it from growing.
Guangzhou, GuangdongAges 18–75 - NCT06635785RecruitingPhase 1/Phase 2
AI-081 for advanced solid tumors
This trial tests a new drug called AI-081 that targets the immune system and tumor blood vessels. It is for people with advanced solid tumors who have not responded to other treatments or cannot take them.
Birmingham, AlabamaAges 18 years+ - NCT06561308RecruitingPhase 2
Immunotherapy plus chemo for advanced endometrial cancer
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT06549855Recruiting
PD-1 inhibitor plus progesterone for fertility preservation in MMRd endometrial cancer
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor) and progesterone hormone therapy to treat early-stage, MMR-deficient endometrial cancer while preserving fertility. It may help young women who want to keep the option to have children in the future.
Beijing, Beijing MunicipalityAges 18–45 - NCT06431685RecruitingPhase 1
Brain radiation, immunotherapy, and chemo for lung cancer spread
This trial tests a combination of low-dose radiation to the whole brain, immunotherapy, and chemotherapy given through a lumbar puncture. It is for people with lung cancer that has spread to the lining of the brain and has not responded to standard treatments.
Chengdu, SichuanAges 18–75 - NCT06430437RecruitingPhase 3
Study of SHR-A1811 for first-line treatment of advanced lung cancer with HER2 mutations
This trial tests a new drug called SHR-A1811 for people with advanced or metastatic non-small cell lung cancer that has a change (mutation) in the HER2 gene. You cannot have had any previous treatment for advanced lung cancer, and the cancer must be measurable outside the brain.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04892849Recruiting
PD-1/PD-L1 immunotherapy plus radiation for solid tumors
This study tests whether combining an immune system medicine (PD-1/PD-L1 inhibitor) with radiation can improve outcomes in people with certain solid cancers. It also looks for blood or tissue “biomarkers” that may explain who benefits most.
Erlangen, BavariaAges 18 years+ - NCT05838729RecruitingPhase 1/Phase 2
RiMO-301 plus radiation with PD-1 therapy for head-neck cancer
This trial studies RiMO-301 injection combined with palliative radiation and a PD-1 immune therapy (pembrolizumab or nivolumab) for head and neck cancer that cannot be fully removed. It aims to see whether this approach can shrink tumors and improve outcomes safely.
Chicago, IllinoisAges 18 years+ - NCT06398418RecruitingPhase 1
Study of R-5780 with PD-1 drugs for advanced solid tumors
This trial tests a new drug called R-5780 combined with standard immunotherapy (PD-1 checkpoint inhibitors) for people with advanced skin cancers or other solid tumors that have stopped responding to treatment. The goal is to see if this combination is safe and helps fight the cancer.
Denver, ColoradoAges 18–80 - NCT06323239RecruitingPhase 2
Radiation plus chemo and immunotherapy for advanced nasopharyngeal cancer
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06239727RecruitingPhase 3
Reduced-dose radiotherapy for stage III nasopharyngeal cancer based on response
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
Fuzhou, FujianAges 18–65 - NCT06214143RecruitingPhase 1/Phase 2
T3011 plus immunotherapy for advanced solid tumors
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
AnyangAges 18 years+ - NCT05772273Recruiting
Test PD-1 drug plus azacitidine and donor cells for AML relapse
This study tests whether combining a PD-1 immune therapy, azacitidine, and low-dose donor lymphocyte infusion (donor immune cells) can treat AML that has come back after a stem cell transplant. It may help some people regain anti-cancer immune activity after relapse.
Suzhou, JiangsuAges Any age - NCT05738694RecruitingPhase 3
Test axitinib plus immunotherapy before kidney cancer surgery
This study tests whether taking axitinib plus an immunotherapy drug (PD-1) before surgery can help people with kidney cancer live longer without the cancer coming back. It’s focused on people who have a higher-risk kidney tumor based on scans and pathology findings.
BeijingAges 18–80 - NCT05700721RecruitingPhase 2
Niraparib and dostarlimab for cancer with growing brain spots
This trial studies whether the medicines niraparib and dostarlimab can slow advanced cancers that have active, growing brain metastases. It is meant for people whose brain tumors can be measured on MRI and who have had at least one previous treatment.
Houston, TexasAges 18 years+ - NCT05467748RecruitingPhase 1/Phase 2
Study drug combo for advanced lung cancer after PD-1 treatment
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Long Beach, CaliforniaAges 18 years+
Hear when a new PD-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pd-1?
- Yes. Clin2 currently lists 300 recruiting pd-1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pd-1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pd-1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.